Wednesday 27 May 2009

Erectile Dysfunction-Mediwatch/General(Updated-31st May)

Erectile Dysfunction (ED) is very common. Estimates are that approximately 152 million men around the world suffer from ED.



Diabetes and erectile dysfunction
Erectile dysfunction (ED) is a common problem amongst men who have diabetes. Some sources indicate anywhere between 35 and 75 per cent of men suffering from diabetes will experience some degree of erectile dysfunction (erection problems) over the course of their lifetime.
Men who have diabetes are thought to develop ED between 10 and 15 years earlier than men who do not suffer from the disease. As men facing diabetes age, erectile dysfunction becomes more common. Over the age of 70, there is a 95 per cent likelihood of facing difficulties with erectile function.



CHARITIES AND INFORMATION

The Sexual Dysfunction Association UK


The Vacuum Pump,Information
NHS (Choices) UK
BUPA-Factsheet UK




MEDIWATCH SPECIFIC

UK-Erectease is available on NHS prescription.

A simple Vacuum Pump for a Fast and Reliable ErectionErectease
Technical Specification (pdf)

HEALTH AND PERSONAL SOCIAL SERVICES FOR NORTHERN IRELAND DRUG TARIFF (Page 146 onwards)



NEWS


UroToday-Erectile Dysfunction (ED)

Erectile dysfunction talks draw capacity audiences

"The response is more than we expected," said Dr. Rick Glowacki, a urologist with the Iowa Clinic. "I think if nothing else, it gives them a forum to hear about it and gives them some privacy. It's a situation where they can just sit there and listen."

Because erectile dysfunction and prostate cancer become more common as men get older, Glowacki said, doctors expect to see an increase in cases as baby boomers age.Erectile dysfunction affects 15 to 30 million men in the United States, according to the National Institutes of Health. Most prostate cancer patients are in their 60s and 70s, but there are also men in their 40s and 50s dealing with the disease, Glowacki said.

Erectile dysfunction talks draw capacity audiences USA-27th May

Sunday 24 May 2009

Russian Demographics at the Year End
Reports from Russian Sources


Upper House Declares Men's Health Under Threat

MOSCOW, December 5 (Itar-Tass) -- Experts of the Upper House of the Russian parliament have expressed concern over declining health of male population in Russia and called to broaden the practice of preventive medical check-ups with special attention focused on male patients who should be subjected to screening tests to diagnose prostate cancer at an early stage.

Life expectancy for men in Russia is 13 years shorter than for women, and death rates among the male population exceed death rates for women almost fourfold, the experts said. Prostate cancer is the most often found cause of men's early death in Russia. Over the past ten years prostate-related sickness rate made up 126 percent, showing 63 percent growth per 100,000 male citizens.

The number of patients suffering from prostate diseases is sharply growing. Experts have established a link between age factor and sickness rates that varies from 20 percent for men aged 41- 50 to 50 percent for those aged 51-60, and is more than 90 percent for men after 80.

"Problems of men's health have come to the foreground now because they seriously affect the demographic situation," said Svetlana Braun, department chief of the Russian Health and Social Development Ministry.

Upper House Declares Men's Health Under Threat Russia-Dec.2008


I've added this to the main page found under April GLOBAL HEALTH

Thursday 21 May 2009

SAFHE 2009-South Africa,Medical Event (20-22nd May)

Tecmed Africa are exhibiting at this event who are distributors for MDW products.Not sure if they have any MDW products on display but of interest anyway.




Welcome

We are delighted to announce that SAFHE 2009 will take place in Cape Town at the Cape Town International Convention Centre, the venue of the highly successful IFHE 2006 event.

The biennial SAFHE conference is designed specifically for the needs of senior people in healthcare in Southern Africa. It boasts a glittering array of speakers from the very top level in our public and private heath-care sectors to the engineers and administrators working in our healthcare services.



The conference is designed to be highly interactive, with debates, presentations, and moderated discussions among all participants offering unrivalled networking opportunities throughout the three days.

The SAFHE biennial conference and exhibition continues to be highly respected and widely recognized in Southern Africa as the forum for debate and interaction between the public and private sectors in healthcare.

SAFHE 2009

DOWNLOAD BROCHURE

Tuesday 19 May 2009

France-Trends in screening for prostate cancer

Abstract:

Background:

Screening for prostate cancer is still in debate. In France, there is no financial barrier for individuals to be screened with the prostate-specific antigen (PSA) test, and there is no recommendation for mass screening.

Methods:

Two nationwide observational studies were carried out in France.

The first one, EDIFICE 1, was conducted in 2005 among a representative sample of 1504 subjects aged between 40 and 75 years and a representative sample of 600 general practitioners (GPs).
The second one, EDIFICE 2, was conducted in 2008 with the same methodology.

Results:

General population: In 2005, 36% of the interviewed male population aged between 50 and 75 years declared having undergone a screening test, compared to 49% in 2008 (OR = 1.63 CI95% 1.25; 2.12).

Prostate cancer screening increased in all age groups, however, the most significant increase can be observed in the population aged between 50 and 54 years: 18% in 2005 versus 35% in 2008 (OR = 2.43 CI95% 1.31; 4.52). This trend for increasing testing will probably be confirmed in the future since 57% of males never screened plan to undergo a test, and only 16% of those who did screening plan to stop.

The expected participation in the future will be close to 70%.

Physicians:

In 2005, 58% of GPs systematically recommended prostate cancer screening for their male consultants ages 50 to 74, in 2008 the figure is 65% (OR = 1.32 CI95%1.04; 1.66).
For prostate cancer screening, a GP's gender has no significant impact. Systematic recommendation for both breast and colorectal cancer screening has an impact on recommending prostate cancer screening as well; OR = 2.9 (CI95% 2.0-4.4) and OR = 2.0 (CI95% 1.3-3.2) respectively. The GP's age is not associated with a higher rate of systematic recommendation.

Conclusions:

We have observed in France a significant growth in prostate cancer screening: more persons screened, more often, at a younger age. Despite the lack of consistent evidence, persons and GPs exposed to mass communication and campaign for breast and colorectal cancer screening might infer that screening is valuable for other conditions.

Trends in screening for prostate cancer


I've added this to the main page found under April GLOBAL HEALTH

Saturday 16 May 2009

ASCO Annual Meeting (Updated-3rd June)

Mediwatch are not attending this event as far as I'm aware.



2009 ASCO Annual Meeting Abstracts


The "New" Prostate Cancer InfoLink highlights relating to this event:

Prostate cancer prevention and screening:an ASCO update 3rd June

ASCO commentary and update no. 2 31st May

ASCO commentary and update no. 1 31st May

What IS being presented at ASCO this year

More papers that ARE being presented at ASCO (group 2)


New Blood Test Greatly Reduces False-positives In Prostate Cancer Screening
ScienceDaily (May 29, 2009) — A new blood test used in combination with a conventional prostate-specific antigen (PSA) screening sharply increases the accuracy of prostate cancer diagnosis, and could eliminate tens of thousands of unneeded, painful, and costly prostate biopsies annually, according to a study led by researchers at Dana-Farber Cancer
Link

Friday 15 May 2009

AFRICA

Nigeria: First Lady Plans N6 Billion Cancer Centre in Abuja


"Abuja — Worried by the increase in reported cases of people with cancer in Nigeria, First Lady, Turai Yar'Adua, has concluded plans to seek solution to the scourge, by proposing to build a N6 billion International Cancer Centre in Abuja.

FCT Minister, Senator Muhammad Adamu Aliero, disclosed this Thursday, at a press conference to announce the Logo/Project of the Centre. Aliero who described the scourge as a terminal disease, said it is made worse by the fact that most Nigerian hospitals and medical centres, lack diagnostic capacity to quickly detect and treat cancer infections, which has greatly compounded the problem."

"The centre, Aliero said, will be the first of its kind in Nigeria and indeed West Africa. According to him, the Centre has been conceptualised by the First Lady after a study has been conducted and visit along with some Nigerian cancer specialists to the M.D. Anderson Cancer Centre in Houston , Texas , which is one of the largest cancer Centres in the world."

"To avoid the project going into oblivion like preceding ones when the initiator is out of office, Aliero said a Board of Trustees of competent, honest and well-trusted Nigerians will be appointed to run the Centre on permanent basis. He also disclosed that Nigerian professional footballers in Europe have indicated their willingness to contribute to the project and hoped that Nigerian entrepreneurs and philanthropists will give maximum cooperation to the project."

"With the prevalence of breast and cervical cancers in women, prostate and other cancers in men; and other cancers in children, the Centre, Akunyili said, will serve as an avenue where "men and women would be screened cognizant of the fact that most of these cancers can be treated if they are detected early." She added that "when there is such a centre on ground, it actually provides the ground for all of us not only the poor, to just stroll into the place and say 'can I be screened?'" Akunyili also canvassed for support for the project and said that since it is not government owned, if it is well managed, it will attract funding and support from international bodies and philanthropists abroad. The moving testimony of a family member of a cancer patient , Mrs. Esther Abe was heard at the ceremony. Abe's father died of prostate cancer , while her mother died of cancer of the pancreas. From the ordeal her parents and the family went through, she said "I cannot wish my enemy the disease.""

Nigeria: First Lady Plans N6 Billion Cancer Centre in Abuja (May 2009)






Cancer:Africa’s Silent Killer

While the world is focused on controlling the spread of HIV/AIDS, tuberculosis and malaria in Africa, the increasing onslaught of cancer has been largely overlooked and ignored. According to the World Heath Organization (WHO), by 2020, African states will account for over a million new cancer cases per year out of a total of 16 million cases world-wide.

Africa remains the continent least prepared to cope with the devastating effects of this new pandemic, having only a few cancer care services available.

The puzzling question for world’s leading medical practitioners at this stage, is how cancer has managed to step outside of its traditional centre point in the West and set foot in fragile Africa. Some answers could be found in the rising pollution that is affecting an increasing number of African cities across the continent, as well as ongoing economic development and, consequently, increased life expectancy and disposable income, which has resulted in more Africans living in urban areas and adopting Western dietary patterns.

All of this have resulted in a gradual increase in cancer cases, particularly breast cancer amongst women and prostate cancer amongst men.

African men and women are not only more likely to get prostate and breast cancer respectively at a younger age, but are also more likely to be diagnosed at a more developed stage of disease. The WHO furthermore identified the underlying causes that had resulted in an increase in cancer cases. Principally, steadily aging populations, high smoking rates, poor nutrition, which is destabilizing the immune system, the spreading of a lifestyle rich in fatty foods and lacking exercise, all exacerbated the problem.

Cancer:Africa’s Silent Killer (2008)

Thursday 14 May 2009

(UK)Prostate Cancer Risk Management Programme

This relates to the post 'New guidance for tests to help detect prostate cancer' and the seven points in the Prostate Cancer Risk Management Programme.

The Real PCRMP Leaflet

The Real PCRMP Leaflet sets out the basic facts about the PSA Test, in particular its advantages and its shortcomings as a test for a man's risk of having prostate cancer.

Unlike the 'official' PCRMP, which runs to 30-odd pages, it outlines, on one A5 page, seven key points that should be explained to a man who is considering, either at his own request or on the suggestion of his GP, having a PSA Test. These points are:

1. The PSA test is a simple blood test which is used to help detect prostate cancer. In its early stages, prostate cancer generally produces no symptoms, so it is important to diagnose the disease before any symptoms arise and while it is still potentially curable. Recent results of a major European trial suggest that treating prostate cancer may significantly prolong a man’s life.

2. A high level of PSA (usually 10 ng/ml and above) is likely to be an indication of prostate cancer and should therefore prompt further investigation. *****My view on the "prompt further investigation" would be to at least have one or more PSA tests before any invasive tests are carried out but just my opinion.*******

3. A moderately raised PSA level (usually 4 ng/ml and above, but this depends on age), means that other factors, including digital rectal examination, ethnicity, family history, prostate volume, PSA history, and free-to-total PSA ratio, should be considered in determining whether to send a man for further tests such as biopsy.

4. However, in three-quarters of such cases, further tests do not detect cancer. There can be other reasons for a moderately elevated PSA (eg urinary infection, enlarged prostate) and these may need treatment.

5. Prostate cancer is not always aggressive or life-threatening. Even if further tests do detect early-stage prostate cancer, a specialist may not be able to tell whether the condition is life-threatening or harmless. This may make treatment choices difficult for both patient and clinician.

6. A low level of PSA (usually below 4 ng/ml, but this depends on age) does not guarantee the absence of prostate cancer. This is because localised prostate cancer does not always produce a raised level of PSA.

7. All these factors have led to the current controversy over the value of the PSA test. However, the uncertainties may be reduced by men having a regular test, ideally on an annual basis. Regular monitoring of PSA levels can highlight any significant or gradual increase, so that even when the PSA is within the ‘normal’ range, one may be alerted to the need for further investigation. ****My View-I agree 100% with this statement but I would then add that further investigation would be by PSA/DRE testing say in six months time unless the readings were very high then much sooner but just my opinion.....**************

The Leaflet can be downloaded as a "pdf" file which can be displayed and printed by the use of a "pdf" Reader. If your computer does not have a suitable Reader, you can download the Adobe Acrobat Reader, which is free, by clicking here.

The Real PCRMP Leaflet is being printed in sufficient quantities for a copy to be held in every GP's surgery in the UK. We do not have the resources, or to be frank, the authority, to mail it to them all ourselves. We therefore rely on patients to pass this information on to their GPs. If you can help in this, please send us an email saying how many copies you want and we will post them to you.

Prostate Cancer Risk Management Programme UK-9th April 2009

(UK)New guidance for tests to help detect prostate cancer

I missed this from last month and also note that I haven't included 'Prostate UK' in the Charity section found under the month of April.




New guidance for tests to help detect prostate cancer



On 20 April the Prostate Cancer Support Federation and Prostate UK release new guidance for GPs to give to men to help them make informed choices when asking for a test that can help to detect prostate cancer. Although the existing guidance, published in 2002, is now considered to be out of date, GPs are still being referred back to it, with its acknowledged flaws.

Any man over the age of 50, or 45 where there is a family history of prostate cancer, is entitled to an annual blood test, PSA, that can help detect prostate cancer at an early stage before other symptoms become known. The PSA test can also indicate other prostate disease. New evidence published (in the New England Journal of Medicine) on 18 March has opened up the debate on prostate screening and delayed the publication of new guidance from the Department of Health. This has many implications for men deciding to have the test and the choices they may need to make afterwards.

John Dwyer, a prostate cancer patient and Chairman of the Prostate Cancer Support Federation, says ‘For two years, patients have been calling for revision of the Government's guidance to GPs on what to say to a man who asks for a PSA test. The added delay in the publication of up-to-date guidance is unacceptable. Although there is much uncertainty about the potential advantages of early testing for prostate cancer, the information men need in order to decide on having a PSA test is simply put, and we believe that all GPs should become aware of it.’

The new seven point guidance has been prepared by the patient group the Prostate Cancer Support Federation and is supported by the country’s leading charity on all prostate diseases, Prostate UK.

‘Prostate cancer is the most common form of cancer to affect men in the UK, claiming the lives of 10,000 a year, so it is important to be informed of the choices available to you in what can be a very confusing area of healthcare,’ says Professor Roger Kirby, founder of the Prostate Centre and chairman of Prostate UK. ‘That’s why this guidance has been created; to help men make an informed choice.’

The seven points in the Prostate Cancer Risk Management Programme can be viewed at www.pcrmp.org.uk

- ENDS -

New guidance for tests to help detect prostate cancer UK-20th April


Here is a link to the Prostate UK quarterly Newsletter where past editions can be viewed simply by changing the "update36.pdf" part of the address to 35 and so on.

Prostate UK-Newsletter (Spring 2009)

TECMED AFRICA-Updated Website

Founded in 1992, Tecmed Africa has evolved into a leading provider of medical equipment and supplies in Africa. In addition to an impressive portfolio of leading international manufacturers within the medical technology sector, Tecmed Africa develops and manufactures their own range of accessories and products. These have been specifically developed for the South African conditions and customer requirements.

Tecmed Africa has now emerged as the leading supplier of state-of-the-art, superior medical solutions to Sub-Saharan Africa, often equipping entire hospitals in the region. We now have branch offices and joint venture agreements in Southern and Eastern Africa




Mediwatch is continually striving to develop the market place by offering rapid, simpler less invasive diagnostic products.
The products are aimed at saving lives and restoring quality of life for people with a variety of Urological conditions.

Biochemistry
Biochemistry: point-of-care tests for PSA and bladder cancer.
- PSAwatch
- Bioscan
- BTA

Diagnostic Ultrasound
Ultrasound: portable and clinic-based diagnostic ultrasound imaging systems.
- Portascan+
- MuItiscan

Urodynamics
Urodynamics: industry standard uroflow and urodynamic systems.
- Urodyn 1000
- Portaflow
- Duet Logic G2
- Duet G3/Sersic

TECMED AFRICA-Urology







Branches or Partnerships

Joint Ventures/Trading

Tuesday 12 May 2009

Discovery and challenge: the state of prostate cancer research

Very interesting debate posted by the “New” Prostate Cancer InfoLink :

Discovery and challenge: the state of prostate cancer research

Posted on May 12, 2009 by Sitemaster

In April this year, the Prostate Cancer Foundation coordinated a media roundtable meeting at the National Press Club in Washington, DC, to address priorities on the prostate cancer research front and related issues. The “New” Prostate Cancer InfoLink is pleased to see that the full transcript of this meeting is now available. You can also watch the entire meeting on video if you prefer.

Discovery and challenge: the state of prostate cancer research

Accrington wife's anger at dying husband's diagnosis delay

I think this highlights the need for improved training within the UK health profession as this families experiance clearly shows.This apparent refusal to carry out the basic initial tests for Prostate Cancer ie PSA and DRE within the UK happens all to often!

It also highlights why the increase in public awareness campaigns relating to Prostate Cancer are so important.
I must also point out that the two initial tests (DRE/PSA) are not direct tests for PC but are valuable indicators for the early detection of possible PC where repeated tests can be carried out before the more invasive tests are called into play.



Accrington wife's anger at dying husband's diagnosis delay


THE furious wife of a terminally-ill father-of-three has hit out at the doctors who failed for 11 months to diagnose that he had prostate cancer.

Hospital bosses said that as prostate cancer in a man so young was ‘virtually unheard of’, they had focused on finding a ‘more likely cause’.
Now Carol, of Cambridge Street, Accrington, is urging young men with repetitive urinary problems to demand they are screened for the cancer.

For two years before his diagnosis his family said he had been suffering constant urinary problems and kidney infections.
While on holiday in Tunisia, Glyn, a former security officer and assistant manager of the Little Chef at Rising Bridge, was admitted to a hospital in the African country with severe water retention.

Doctors discovered he had an over enlarged prostate and advised them to seek medical attention when he returned to the UK.

The next day he was flown back to England and saw doctors from Royal Blackburn Hospital.
But Carol said medics dismissed the findings of the Tunisian doctors.

She said: “I will never forget that day.

“We flew back to Britain and saw Glyn’s urologist at Royal Blackburn Hospital and the doctors said ‘Your husband is far too young to have problems with his prostate.’ “11 months later he had a prostate examination and a biopsy. We were called into a room and was told he had prostate cancer.”

Carol said they should have done same tests carried out by Tunisian doctors. “It shouldn’t have been left it until 11 months later when they tested him”, she said.
Mr Fielding has just completed his 10th round of chemotherapy. The cancer has spread to his bladder and bones.

Doctors predict Glyn has just eight months to live but his condition has deteriorated over the last week.

East Lancashire Hospitals NHS Trust said tests for prostate cancer were only carried out if there were clinical indicators which suggested the likelihood of cancer being present.
It is not NHS policy to routinely screen for prostate cancer. However it can now be done at the request of the patient.

Accrington wife's anger at dying husband's diagnosis delay UK-12th May

Saturday 9 May 2009

19th - 23rd January 2009 Annual Evidence Update on Urinary Incontinence

19th - 23rd January 2009 Annual Evidence Update on Urinary Incontinence

Introduction: Urinary Incontinence
By Alison Brading, Emeritus professor of Pharmacology, University Department of Pharmacology, Mansfield Road, Oxford OX1 3QT

Urinary incontinence is normally not life-threatening, and yet may have a greater detrimental effect on the quality of life of those suffering from it than many more serious conditions. A great deal of literature is published yearly, and the aim of this annual evidence update is to direct attention to the relevant information gleaned from papers published about male and female urinary incontinence in recent years.
We have considered the more traditional pharmacological and surgical treatment of adult male and female stress and urge incontinence, including post-prostatectomy incontinence in men, and, as well as more conservative approaches now cover the rapidly growing use of botulinum toxin injected into the bladder wall as a treatment for urge incontinence.
We hope that this will provide a useful source for busy clinicians, and will help to improve treatment of this devastating condition.

2009 Annual Evidence Update on Urinary Incontinence

I've added this to the main thread found under the month of April URODYNAMICS INFORMATION

Friday 8 May 2009

Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence, Controversies and Future Perspectives - Abstract

Friday, 08 May 2009

Department of Urology, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.

The most recent epidemiological survey revealed that the mortality rate for prostate cancer in Japan has increased and has been getting very close to that in the USA, where it has decreased since 1992.

The low exposure rate of prostate-specific antigen (PSA) screening in Japan and the high exposure rate of PSA screening in the USA may result in completely deferent trends in the mortality rate of prostate cancer between the two countries.

The Japanese Urological Association recommends PSA-based screening for men at risk of prostate cancer at age 50 years or older in general and 45 years or older in men with a family history of prostate cancer within first generation relatives.

The fact sheet on screening for prostate cancer should indicate the most recent reliable clinical research on screening for prostate cancer and its demerits including false-negative and false-positive PSA test results and prostate biopsy, overdetection and overtreatment.

However, it should be explained to the public that the demerits for PSA screening will be clarified step by step during screening, and in general, men having more information on screening results (PSA level, pathological findings of biopsy specimens, clinical stage, etc.) can understand their current situation better than those having no information on screening results, including PSA levels.
Written by: Ito K.

Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence, Controversies and Future Perspectives-Abstract Japan-8th May

Wednesday 6 May 2009

Prostate Screening Trust

Patients Power

As a patient group who believe in screening we will be offering blood test to men and follow up with an individual management program.
Contact info@prostatescreeningtrust.co.uk for dates and location
We believe that patients should be treated as individuals and not follow a “one treatment fits all regimes”.
Patients are becoming more aware of the options available provided they are diagnosed as early as possible. Watchful watching or active monitoring/ surveillance will increase but should be part of a healthier living programme to improve quality of life.
This change in attitudes will develop patient power were men and their families take control of their lives and the duty of care available across the UK and EU.



Prostate Screening Trust


(I've added this to the main thread 'PSAwatch-IN ACTION!' found in the month of April)

Family History Clinic

I missed this update from The Birmingham Prostate Clinic (21st April 2009) so will give it a post all of it's own especially as they have been using PSAwatch for quite some time:


NEW CLINIC TO PROTECT MEN WITH A FAMILY HISTORY OF PROSTATE CANCER

A new clinic has been established for men with a history of prostate cancer in their family in order to protect them from the disease.

The Birmingham Prostate Clinic has established a new service for men who have a family history of the disease to protect them by providing individually-tailored care.

Prostate cancer is the most common cancer among men, with 34,000 men being diagnosed with the disease each year.

Family history is a major factor in risk of developing prostate cancer. For example, if a first degree relative is diagnosed with prostate cancer before the age of 60, your own risk increases by about four times the average risk. A first degree relative is a father or son.

Clinical Director, Consultant Urologist Alan Doherty explains: “Whenever I see a patient who is diagnosed with prostate cancer, particularly if they are aged below 60, I advise them to speak to their first degree male relatives about having a PSA test.

“Unfortunately, anxieties about family history of prostate cancer are sometimes treated as unnecessary worry, particularly if patients are fairly young.
“However, information about family history is an important part of understanding a man’s risk of prostate cancer and offering the right care and surveillance for him.
“Clinics focusing on family history have been developed in other areas of cancer services, such as for breast and colon cancer. We are applying the same principle to prostate cancer – that people with a family history of a disease need individually tailored care.”

Mr Doherty emphasises that the age of your relative when they develop prostate cancer is very significant.

By the age of 80, around half of all men have some cancer cells in their prostate, but these are usually slow growing and unlikely to cause death.

When prostate cancer develops at a younger age – in forties and fifties – this can be a more aggressive form of the disease which is more likely to spread to other parts of the body.
“Therefore, if your father is diagnosed with prostate cancer at the age of 75, it will reflect less of a family risk than if your brother is diagnosed at the age of 53,” explains Mr Doherty.

It is also important to look at incidence. If more than one first degree relative is diagnosed with prostate cancer, your risk increases fourfold, regardless of their age when the disease develops.
There is also evidence that a faulty gene called BRCA2 linked to breast cancer, in men can increase the risk of prostate cancer fivefold.

The average lifetime risk of developing prostate cancer is one in 12.

The Birmingham Prostate Clinic recommends that men with a family history of prostate cancer have a PSA test every one or two years.

PSA stands for Prostate Specific Antigen, a protein made by the prostate which naturally leaks into the bloodstream when the prostate is damaged.

Annual tests are advised if a relative was diagnosed with prostate cancer under the age of 60 and two yearly tests if over that age.

Patients are advised to keep a record of PSA test results on a record card which enables doctors to see how PSA is behaving over time.

“For example, a patient may have a PSA level which is within the thresholds, or recommendations for a patient’s age, but if it has risen significantly during a single year, this would indicate further tests may be necessary,” says Mr Doherty.

The Birmingham Prostate Clinic offers the new 10 minute PSA test, which enables patients to have the test and discuss their results with the urologist during a single visit.
This is particularly beneficial for patients with a family history of prostate cancer who are likely to experience higher levels of anxiety while waiting for results.

Family History Clinic


(I've added this to the main thread 'PSAwatch-IN ACTION!' found in the month of April)

Tuesday 5 May 2009

Brazil-HOSPITALAR (2nd to 5th June 2009)

A bit early but I'll make a start on this event as it's a major affair!




ABOUT THE EVENT

HOSPITALAR 2009 – 16th International Fair of Products, Equipment, Services and Technology for Hospitals, Laboratories, Pharmacies, Clinics and Medical Offices – the largest healthcare event in Latin America and second worldwide – will present its largest edition ever from June 2nd to 5th.

The fair will occupy a total area of 82,000 sqm in the exhibition halls of Expo Center Norte, 20% more than the previous edition, gathering around 1,200 exhibiting companies from over 30 countries. In four days of event, HOSPITALAR 2009 is expected to receive more than 78 thousand professional visitors, including directors of hospitals, clinics and laboratories, medical doctors, nurses, entrepreneurs and other healthcare professionals.

HOSPITALAR 2009 will also be the first fair to occupy entirely the new facilities of Expo Center Norte, which now offers much more exhibition space, a new Entry Hall, 17 modern auditoriums, air-conditioning in all the complex, food service, parking lot for 20 thousand vehicles and many other services for exhibitors and visitors.

To be held during a period of expectation as to the directions of the global economy, HOSPITALAR’s 16th edition will be an important performance indicator of the health area, a sector which has a turnover of more than R$ 200 billion a year and represents about 8% of the national GDP.

The 2008 edition of the fair generated R$ 4.4 billion in sales and received visitors from all over Brazil and from nearly 70 countries. During the event, the visitors have the opportunity to get to know what’s new in terms of products, equipment and technologies for the healthcare sector, establishing commercial contacts with reflections for over 90 days after the fair. The expectation around this edition is positive, based on the high volume of investment made by hospitals and industries, aiming to expand and qualify their services.

HOSPITALAR 2009 grows 20% and
prepares its largest edition in 16 years






Hospitalar Trade Show 2009: Bigger and Better (23/04/2009)
HOSPITALAR Trade Show is the most complete healthcare technologies fair in Latin America. The fair is established as the leading trading point for new technologies, representing a great opportunity for British companies to promote products and services while updating hospitals, health clinics and laboratories.

HOSPITALAR 2008 received 78,000 professional visitors that came from all over Brazil and 72 other countries. The increasing influence of the event over the Latin American market was shown once again through the largest groups of visitors (apart from Brazilians) coming from Argentina, Peru, Chile, Bolivia, USA, Uruguay, Colombia, Venezuela, Equador, Paraguay and Mexico.

UK Trade & Investment and Yorkshire Medilink are organising the biggest UK pavillion ever, with 200 m and 17 companies. This year's edition will offer a showcase area and a UKTI/Medilink facilitation area to support the exhibitors.

UK Pavilion exhibitors (Only need to show the one):

Mediwatch (http://www.mediwatch.com/)

Hospitalar Trade Show 2009: Bigger and Better (23/04/2009)

FUTURE EVENTS AND LATEST NEWS (Updated-28th)


HOSPITALAR 2009 grows 20% and
prepares its largest edition in 16 years
2nd-5th June

Texas Urology Society (TUS) Annual Meeting,June 4th-6th



Understanding Urodynamics-Joint RCOG/BSUG Meeting 11-12th May 2009


STUFF THAT MAYBE DID BUT NOW DOESN'T FIT IN WITH THE TITLE...

Five year global distribution agreement secured with Inverness Medical Innovations-16 March 2009

MEDIWATCH ANNUAL REPORT AND ACCOUNTS 2008Issued 23rd February 2009

Preliminary Results for the year ended 31 October 2008-Issued 26 January 2009


In my view the best information on PSA testing and the future that I have seen to date!

Events-Update

Mediwatch were due to attend/exhibit or possibly run one of the courses at:

"From May 21 to May 24, 2009 in Napa Valley, California, the Urology Department of McGill University, the Obstetrics and Gynecology Department of Queen’s University and the Cleveland Clinic will be presenting a course on urogynecology and female urology where 200 North American urologists and gynecologists are expected to attend. This course will focus mainly on: - Urodynamics and cystoscopy - New technology - Pelvic pain - Prolapses The program will include prestigious presenters, the best and the most competent that this specialty can offer. I invite you to visit our website at www.urogyne2009napa.com for more information."
Events

I am pretty sure this event was cancelled about a month ago until a new date could be arranged.The event looks to have been now rescheduled to September 26th-27th:

Attend the first north american STATE-OF-THE-ART COURSE ON THE URETHRA

ASCRS Annual Meeting-2nd-6th May (Updated-17th May)

Mediwatch are exhibiting here:

Updated Final Program

ASCRS 2009 Annual Meeting,May 2nd–6th


The American Society of
Colon and Rectal Surgeons-Annual Meeting Abstracts

Sunday 3 May 2009

AUA:Prostate-Specific Antigen Best Practice Statement:2009 Update

The American Urological Association (AUA) goals are for the advancement of urological clinical care through education,research and in the formulation of health care policy,which although directed towards the US will obviously be taken on board by individual countries in full/part or as an informative aid in setting up their own health care policies.

Prostate-Specific Antigen Best Practice Statement:2009 Update AUA-27th April 2009

Prostate-Specific Antigen (PSA) Best Practice Policy:2000" AUA-February 2000


My view and MY VIEW ONLY:

First and foremost it's up to the individual whether he gets tested or not!

The AUA 2009 Update for the initial testing for possible PC is a much needed revision from the 2000 version especially in the reduction of unnecessary biopsies.

2000 version:

6. When is a prostate biopsy indicated?

Although an abnormal DRE or an elevated PSA may suggest the presence of prostate cancer, cancer can only be confirmed by the pathologic examination of prostate tissue. A urologist should be consulted for a prostate biopsy when any of the following findings are present:

1 PSA is 4.0 ng/mL or more;
2 A significant PSA rise from one test to the next; or
3 DRE is abnormal.

2009 Update (My interpretation):

PSA test to be made available (USA) to men 40 years and older who may or may not show signs of possible PC but have a family history of PC or/and after being informed of the +/-'s attributed to the two initial tests (DRE and PSA) they decide to get tested.

Relating to the flow chart on page 9 of the 2009 Update and after a DRE/PSA test:

1. DRE abnormal/PSA low
for age (consider possible
causes: prostate cancer, BPH,
infection, trauma, etc)
2. PSA high for age or
3. DRE abnormal and PSA
high

THEN

Counsel patient regarding both
risks and benefits of biopsy

CHOICE

Biopsy done,extended, local anesthesia OR Biopsy not done AND then Return regularly for PSA and DRE

Will add to another day








Below are some articles relating to the AUA statement:


Testing for prostate cancer 10 years earlier Macleans-5th May


THE "NEW" PROSTATE CANCER INFOLINKThe new AUA guidance on PSA testing:a critical analysisThe “New” Prostate Cancer InfoLink-2nd May

AUA:Urologists Support Baseline PSA Test at Age 40 MedPage Today-29th April



AUA recommends individualised PSA testing for men aged 40 or olderUrosource-28th April


AUA counters mainstream recommendations with new best practice statement on PSA testingBio-Medicine-27th April